department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Qulipta · pharmadog

pharmadog
drugs
Qulipta

drug

patient view →

atogepant

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.

all catalysts(6)

approval · 6

QULIPTA (ATOGEPANT) — FDA approval

QULIPTA (ATOGEPANT) — FDA approval

QULIPTA (ATOGEPANT) — FDA approval

QULIPTA (ATOGEPANT) — FDA approval

QULIPTA (ATOGEPANT) — FDA approval

QULIPTA (ATOGEPANT) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Qulipta

generic

atogepant

MOA

12.1 Mechanism of Action Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.

indication

Migraine

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 28, 2026

83 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (20)

Feb 27, 2043method-of-use (U-4234)US 12350259
Sep 27, 2042method-of-use (U-4355)US 12465598
Jul 29, 2041method-of-use (U-3534)US 12090148
Jul 29, 2041method-of-use (U-3534)US 12090148
Jul 29, 2041method-of-use (U-3534)US 12090148
Jun 6, 2039method-of-use (U-3534)US 12383545
Jun 6, 2039method-of-use (U-3534)US 12383545
Jun 6, 2039method-of-use (U-3534)US 12383545
Jan 30, 2035formulationUS 10117836
Jan 30, 2035formulationUS 10117836
Jan 30, 2035formulationUS 10117836
Mar 13, 2033compositionUS 9850246
Mar 13, 2033compositionUS 9850246
Mar 13, 2033compositionUS 9850246
Jul 19, 2032compositionUS 8754096
Jul 19, 2032compositionUS 8754096
Jul 19, 2032compositionUS 8754096
Nov 10, 2031compositionUS 9499545
Nov 10, 2031compositionUS 9499545
Nov 10, 2031compositionUS 9499545

FDA exclusivities (6)

Sep 28, 2026NCENew Chemical Entity (5y)83d
Sep 28, 2026NCENew Chemical Entity (5y)83d
Sep 28, 2026NCENew Chemical Entity (5y)83d
Apr 17, 2026I-909Indication (3y)
Apr 17, 2026I-909Indication (3y)
Apr 17, 2026I-909Indication (3y)

Data sources

openFDA · ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

drugQULIPTA24 co-mentions · 6 sources
tagApproval24 co-mentions · 6 sources
tagSmall Molecule12 co-mentions · 6 sources

Trials studying atogepant

phase3A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migrainerecruitingn=450
—Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migrainerecruitingn=3,000
phase3Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migrainecompletedn=75
phase3Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraineactive not recruitingn=1,300
phase3A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Yearsrecruitingn=420
phase4Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Studyrecruitingn=1,335
phase3Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migrainerecruitingn=430
phase3A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migrainecompletedn=596

more trials →